GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...

which also sells a version of liraglutide approved for obesity, called Saxenda. “There are many people on this drug, and they will benefit by another generic version of it,” Dr. Harlan ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers ...

The cost-effectiveness agency for England and Wales has recommended Saxenda (liraglutide) as a treatment option for people with a body mass index (BMI) of 35 or more, and who are also pre-diabetic ...

The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the conventional injected liraglutide (Saxenda®).

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

The GLP-1 receptor agonists studied included semaglutide (Wegovy/Ozempic, Novo Nordisk), exenatide (Bydureon, AstraZeneca), liraglutide (Saxenda, Novo Nordisk) and dulaglutide (Trulicity ...